Warner Chilcott Prevails Vs. Teva In Sarafem Patent Suit

Law360, New York (August 6, 2004, 12:00 AM EDT) -- A federal district court has upheld the validity of a patent for Irish drug maker Warner Chilcott’s pre-menstrual dysphoric disorder treatment Sarafem, rejecting a challenge by Israeli generics maker Teva Pharmaceuticals.

In a 90-page decision, Chief Judge Sarah Barker of the U.S. District Court for the Southern District of Indiana found in favor of Lilly and Warner Chilcott, and upheld the validity of the Sarafem patent. As a result, injunctive relief is available to Warner Chilcott until the expiration of the patent in May 2008....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.